Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4212881
Max Phase: Preclinical
Molecular Formula: C13H14N4
Molecular Weight: 226.28
Molecule Type: Small molecule
Associated Items:
ID: ALA4212881
Max Phase: Preclinical
Molecular Formula: C13H14N4
Molecular Weight: 226.28
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccc2nc(N(C)C)c3ccnn3c2c1
Standard InChI: InChI=1S/C13H14N4/c1-9-4-5-10-12(8-9)17-11(6-7-14-17)13(15-10)16(2)3/h4-8H,1-3H3
Standard InChI Key: WXSSYENPSZWOLM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 226.28 | Molecular Weight (Monoisotopic): 226.1218 | AlogP: 2.26 | #Rotatable Bonds: 1 |
Polar Surface Area: 33.43 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 1.07 | CX LogP: 2.91 | CX LogD: 2.91 |
Aromatic Rings: 3 | Heavy Atoms: 17 | QED Weighted: 0.64 | Np Likeness Score: -1.77 |
1. Patinote C, Bou Karroum N, Moarbess G, Deleuze-Masquefa C, Hadj-Kaddour K, Cuq P, Diab-Assaf M, Kassab I, Bonnet PA.. (2017) Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors., 138 [PMID:28750313] [10.1016/j.ejmech.2017.07.021] |
Source(1):